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Abstract
Background
We evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscu-
lar anomalies in an IBS-type mouse model of gastrointestinal motor dysfunctions elicited by
Herpes Simplex Virus type 1 (HSV-1) exposure.
Methods
Mice were inoculated intranasally with HSV-1 (102 PFU) or vehicle at time 0 and 4 weeks
later by the intragastric (IG) route (108 PFU). Six weeks after IG inoculum, mice were ran-
domly allocated to receive oral gavage with either S. boulardii (107 CFU/day) or vehicle.
After 4 weeks the following were determined: a) intestinal motility using fluorescein-iso-
thiocyanate dextran distribution in the gut, fecal pellet expulsion, stool water content, and
distal colonic transit of glass beads; b) integrity of the enteric nervous system (ENS) by
immunohistochemistry on ileal whole-mount preparations and western blot of protein
lysates from ileal longitudinal muscle and myenteric plexus; c) isometric muscle tension
with electric field and pharmacological (carbachol) stimulation of ileal segments; and d)
intestinal inflammation by levels of tumor necrosis factor α, interleukin(IL)-1β, IL-10 and
IL-4.
Results
S. boulardii CNCM I-745 improved HSV-1 induced intestinal dysmotility and alteration of
intestinal transit observed ten weeks after IG inoculum of the virus. Also, the probiotic yeast
ameliorated the structural alterations of the ENS induced by HSV-1 (i.e., reduced peripherin
immunoreactivity and expression, increased glial S100β protein immunoreactivity and neu-
ronal nitric oxide synthase level, reduced substance P-positive fibers). Moreover, S. boular-
dii CNCM I-745 diminished the production of HSV-1 associated pro-inflammatory cytokines
in the myenteric plexus and increased levels of anti-inflammatory interleukins.
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Conclusions
S. boulardii CNCM I-745 ameliorated gastrointestinal neuromuscular anomalies in a mouse
model of gut dysfunctions typically observed with irritable bowel syndrome.
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that significantly
affects patient quality of life [1,2]. It is the most commonly diagnosed gastrointestinal condi-
tion affecting up to 10−15% of the population in industrialized countries [2,3]. IBS covers a
range of polymorphous clinical manifestations, such as abdominal distension, pain or dis-
comfort, and changes in bowel habits with a chronic irregular course [2]. Based on the preva-
lent symptoms three types of IBS are described: diarrheal, constipation and alternating
forms. Visceral hypersensitivity, gastrointestinal dysmotility, post infectious reactivity,
brain-gut interactions, microscopic inflammation, and gut dysbiosis, have been implicated
in the pathogenesis of IBS and demonstrate the challenge that IBS still represents for clini-
cians and researchers.
The etiology of IBS has not been completely established to date. Neuroplasticity disorders
of the enteric nervous system (ENS) have been described in functional and inflammatory
bowel diseases [4]. Although the underlying process remain elusive, immune-inflammatory
mechanisms have been hypothesized [5]. Infiltrating CD3 lymphocytes have been detected in
the myenteric plexus of patients with severe gastrointestinal motor disorders requiring surgical
resection, such as gastroparesis, chronic intestinal pseudo-obstruction, and slow-transit consti-
pation [6]. Abnormal association between mast cells and nerve fibers, and increased release of
tryptase and histamine have also been described in IBS patients [7], suggesting that histamine
and other bioactive substances released from mast cells infiltrating the gut mucosa could affect
the behavior of nearby enteric nerves [8].
The limited knowledge of the cellular and molecular mechanisms underlying IBS com-
bined with the lack of reliable animal models that reproduce all aspects of this debilitating
disease have hampered the search for effective treatments. Our research group has estab-
lished an animal model of persistent infection with Herpes simplex virus type 1 (HSV-1) in
the ENS [9]. The persistent viral infection of the ENS leads to gastrointestinal neuromuscular
structural and functional anomalies (i.e. gut dysmotility followed by periods of regular GI
transit) and to a slight mucosal inflammation mimicking, at least in part, those described in
IBS [9].
Probiotics are an attractive non-pharmacological option for the treatment of IBS since
these live microorganisms exert beneficial effects on gut homeostasis [10]. They suppress the
growth and binding of pathogenic bacteria, improve the barrier function of the intestinal epi-
thelium, and tune the immune activity of the host [10,11,12], either by direct interaction with
immune cells or by production of by-products of fiber fermentation [13]. Moreover, probiotics
have been shown to improve bowel dysmotility [14]. Among probiotics, Saccharomyces boular-
dii CNCM I-745 is a non-pathogenic yeast widely used in the prophylaxis and treatment of
diarrheal diseases [15]. It enhances gastrointestinal barrier function and strongly modulates
mucosal inflammatory and immune responses [15]. Since it has been reported that S. boulardii
CNCM I-745 supplementation significantly improves the quality of life of IBS patients [16], we
designed this study to investigate the effects of this probiotic yeast supplementation in our
IBS-type murine model of HSV-1 induced gut dysmotility.
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Materials and methods
Animals
Six-week-old C57BL/6J male mice, weighing 18±1.3 g, were purchased from Envigo Laborato-
ries (Oderzo, Italy) and housed in groups of 4 per cage, in a temperature-controlled environ-
ment (22 ± 2˚C) under a 12-hour light-dark cycle. Standard mouse chow food and water were
provided ad libitum. All experimental protocols were approved by the Animal Care and Use
Ethics Committee of the University of Padova under license from the Italian Ministry of
Health, and they were in compliance with the National and European guidelines for handling
and use of experimental animals.
HSV-1 strains
HSV-1 strain 16 was propagated in Vero cells (American Type Culture Collection, Manassas,
VA). The viral titer was quantified using the plaque assay. Vero cells grown in 12-well plates
(2x105 cells per well) were infected with 10-fold serial dilutions of virus. After 2 hours, mono-
layers were then covered with nutrient medium supplemented with 2% sterile agar to prevent
the virus spreading to nearby uninfected cells. Plates were incubated for additional 46 hours
and plaques produced at particular dilution were counted to provide the number of infectious
virions as means plaque-forming units (PFU) per milliliter [9]. Viral stocks were aliquoted and
stored at −80˚C. Each aliquot was used in a single experiment.
S. boulardii preparation
Lyophilized S. boulardii CNCM I-745 (Sb, Biocodex, France) was re-suspended in sterile phos-
phate buffered saline (PBS) and left at room temperature for 10 minutes. The titer of the solu-
tion was periodically checked on Sabouraud agar plates. S. boulardii CNCM I-745 (107 CFU/
mouse) was administered daily by oral gavage in a total volume of 100 μL. Sterile PBS was used
as vehicle.
Mice infection and treatments
After a 1-week acclimatization period, mice were randomly assigned to two groups (HSV-1
infected and controls), and further divided into two subgroups as shown in Fig 1. Mice were
infected by intranasal instillation of HSV-1 (102 PFU/mouse) in a total volume of 10 μL, or
received an equal volume of vehicle (controls). Mice were then monitored daily for the emer-
gence of any neurological deficit. Four weeks later, the infected animals were inoculated again
with HSV-1 (100 μL; 108 PFU/mouse) by intragastric (IG) gavage (24 gauge, 9-cm catheter).
Controls received equal volumes of Vero cell lysate.
Besides randomization between HSV-1 infection and control, mice were randomly as-
signed to receive either S. boulardii CNCM I-745 supplementation or placebo daily (Sb-supple-
mented or vehicle-treated mice; Fig 1). S. boulardii CNCM I-745 supplementation started 4
weeks after IG vehicle/viral inoculum and continued for 6 weeks. Food intake and body weight
changes were recorded weekly throughout the experiment. Animals were sacrificed 10 weeks
after IG viral inoculum by cervical dislocation [17] (Fig 1).
Neurological assessment
Starting with IN viral inoculum neurological integrity of each mouse was assessed at weekly
interval by a blinded observer using a validated scoring system [18]. Six tests were performed
to evaluate sensorimotor functions: (1) spontaneous activity; (2) symmetry in the movement
S. boulardii CNCM I-745 improves HSV-1 induced intestinal dysmotility
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of the four limbs; (3) forepaw outstretching; (4) climbing; (5) body proprioception; and (6)
response to vibrissae touch.
Histopathological evaluation
Ileal (5−10 cm from ileocecal valve) and colonic (1−5 cm from the cecum) specimens were
fixed in formalin and paraffin embedded. Sections (5 μm thick) were stained with hematoxy-
lin/eosin. Slides (6−8/mouse) were assessed in a blinded manner. A minimum of 10 indepen-
dent fields per animal were examined at low (x10) and high (x20) magnification using an
inverted Leica microscope equipped with a digital camera.
Whole mount staining
Segments of distal ileum (4 cm long) were flushed with PBS, filled with fixative solution (4%
neutral paraformaldehyde, 0.2% saturated picric acid in 0.1 M PBS), tied at both ends, and
immersed in the same fixative solution. After 1 hour at 22˚C, tissues were washed in PBS (3 x
10 min) and stored at 4˚C until used. Under a dissecting microscope, a small incision was
made with tweezers on a segment of ileum (approximately 1 cm long) and the longitudinal
muscle layer with the adherent myenteric plexus (LMMP) was peeled off. The tissue sheets
were gently stretched and pinned down on a wax support, washed twice with PBS, incubated
in permeabilization buffer (0.5% Triton-X100 in PBS) then stained at room temperature for 16
hours with the appropriate rabbit primary anti- βIII-Tubulin (Sigma-Aldrich, Milan, Italy),
anti-peripherin or anti-S100β (Millipore, Milan, Italy) antibodies (Table 1). Antibodies were
diluted 1:400 in PBS/0.2% TritonX100/2% BSA [19]. TRITC-labeled secondary antibodies
(Invitrogen, Milan, Italy; Table 1) were diluted 1:200 in PBS/0.2% TritonX100/2% BSA and
incubated for 2 hours at room temperature to detect the immuno-complexes. Following exten-
sive washing, in PBS/0.2% TritonX100 (3 x 10 min), samples were visualized with a Leica
TCSNT/SP2 confocal microscope (original magnification x40). Microscope settings were
established to collect images below saturation and were kept constant for all images.
Fig 1. Scheme for the experimental course of the S. boulardii CNCM I-745 supplementation in HSV-1
infected mice. Mice were intranasally (IN) inoculated with Vero cell lysate (vehicle) or HSV-1 (102 PFU). After 4
weeks, mice received an intragastric inoculum (IG) of Vero cell lysate (vehicle) or HSV-1 (108 PFU). Mice were
randomly allocated to receive 100 μL of either phosphate buffered saline (vehicle) or S. boulardii CNCM I-745 by
daily oral gavage starting 4 weeks after IG viral inoculum. Animals were sacrificed 10 weeks after IG viral
inoculum. n = 8 mice for each experimental group.
https://doi.org/10.1371/journal.pone.0181863.g001
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Immunoblot analysis
At the time of sacrifice, the small intestine was removed, washed in ice-cold PBS, cut into
pieces 1 cm in length and placed over a sterile glass rod. The LMMP was quickly peeled off
under a dissecting microscope (Leica). LMMP were homogenized in RIPA lysis buffer (150
mM NaCl, 50 mM Tris-HCl, 0.25% sodium deoxycholate, 0.1% Nonidet P-40, 100 μM NaVO4,
1 mM NaF, all provided by Sigma-Aldrich) containing protease inhibitors (0.5 mM EDTA,
0.1 mM PMSF, 1 μM leupeptin, 150 nM aprotinin). After 45 min at 4˚C, particulate material
was removed by centrifugation (15,000 xg for 30 min at 4˚C) and protein concentration in the
supernatants was determined using the bicinchoninic acid method (Pierce, Milan, Italy). Pro-
teins were fractionated through an SDS-PAGE gel, immobilized onto a nitrocellulose mem-
brane, and subsequently subjected to immunoblot analysis. The membranes were blocked for 1
hour with 5% non-fat dried milk in PBS with 0.05% Tween 20, then probed with the appropriate
primary antibody (Table 1; 1:500 in PBS/0.05% Tween 20/5% non-fat dried milk for 16 hours at
4˚C). Immuno-complexes were detected using horseradish peroxidase-conjugated secondary
antibodies (Table 1; Sigma-Aldrich; 1:200 in PBS/0.05% Tween 20/5% non-fat dried milk for 2
hours at room temperature) and enhanced chemiluminescent system (Millipore). Images were
captured using Hyper Film MP (GE Healthcare, Milan, Italy). Anti-mouse β-actin (Sigma-
Aldrich) was used as the loading control. Densitometry analysis of the band intensity was per-
formed using the ImageJ software (US National Institutes of Health).
ELISA analysis
LMMPs were placed in ice-cold PBS (1:10 wt/vol) supplemented with protease inhibitors (0.1
mM PMSF, 1 μM leupeptin, 150 nM aprotinin) and homogenized for 30 seconds. Cellular
debris was removed by centrifugation (10,000 xg for 10 min at 4˚C). Levels of tumor necrosis
factor (TNF)-α and interleukin (IL)-1β, IL-4, and IL-10 in the clear supernatants were deter-
mined by enzyme-linked immunosorbent assay (ELISA), using commercially available kits
(eBioscience, Prodotti Gianni, Milano, Italy). The assays were conducted in accordance with
the manufacturer’s recommended protocols.
In vivo gastrointestinal transit
100 μL of fluorescein-isothiocyanate dextran (70,000 Da molecular weight; Santa Cruz Bio-
technology, Heidelberg, Germany) dissolved in PBS (6.25 mg/mL) was administered via a
Table 1. Primary and secondary antibodies used in the study.
PRIMARY ANTIBODIES
ANTIGEN (HOST) CLONE SOURCE APPLICATION
β-Actin (mouse) AC-15 Sigma-Aldrich WB
βIII-Tubulin (rabbit) polyclonal Couvance WM
nNOS (rabbit) polyclonal Invitrogen WB
Peripherin (rabbit) polyclonal Millipore WM, WB
S100β (rabbit) EP1576Y Millipore WM, WB
Substance P, SP (rabbit) polyclonal ImmunoStar WM
SECONDARY ANTIBODIES
ANTIGEN (HOST) CLONE SOURCE APPLICATION
goat anti-rabbit IgG HRP-conjugate Sigma-Aldrich WB
goat anti-rabbit IgG Rhodamine-conjugate Chemicon WM
goat anti-mouse IgG HRP-conjugate Sigma-Aldrich WB
WB, western blot; WM, whole mount.
https://doi.org/10.1371/journal.pone.0181863.t001
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orogastric tube into the stomach. Animals were placed in their original cages then sacrificed
after 60 min by cervical dislocation. The abdomen was opened and the gut carefully removed
avoiding stretching. Stomach and cecum were examined separately; small intestine and colon
were divided into eight and two identical segments, respectively. Luminal contents were col-
lected and clarified by centrifugation (10,000 xg, 15 min, 4˚C). Fluorescence analysis was per-
formed at 494/521 nm (Hitachi F2000; Hitachi, Tokyo, Japan). Gastrointestinal transit was
calculated as the geometric center (GC) of distribution of the fluorescent probe using the for-
mula:
GC ¼ S ð% of total fluorescent signal per segment segment numberÞ=100:
Ex vivo contractility studies
Ex vivo contractility studies were performed on distal 10 cm ileal segments. Neuronal-medi-
ated contractions were evoked through electrical field stimulation (EFS; 2–40 Hz, 1-ms pulse-
duration, 10-s pulse-trains, 60 V) using platinum electrodes connected to an S88 stimulator
(Grass Instrument, Quincy, MA) or carbachol (Sigma-Aldrich) at concentrations ranging
from 10−9 to 10−4 M.
Bead latency test
As previously described [20], assessment of distal colonic transit and emptying, was performed
by placing a spherical 2-mm glass bead 2 cm proximal to the anal opening using a fire-polished
glass rod lightly coated with Surgilube lubricating jelly. After bead insertion, mice were placed
in individual plastic cages lined with white paper to aid visualization of bead expulsion. The
time required for expulsion of the glass bead was determined to the nearest 0.1 min for each
animal.
Fecal pellet expulsion and water content
To enumerate fecal pellets expulsed, each mouse was placed in a separate clean cage and
observed for 60 minutes [21]. Fecal pellets were collected immediately after expulsion and
placed in sealed 1.5 mL tubes. Tubes were weighed to obtain the wet weight of the stools,
which were then dried overnight at 65˚C and reweighed to obtain the dry weight. The stool
water content was calculated from the difference between the wet and dry stool weights and
expressed as a percentage.
Statistical analysis
All results were given as mean ± standard error of the mean (SEM), except for distribution of
the fluorescent probe, which was presented as median ± SEM. Differences in the mean for the
different experimental groups was tested using one-way ANOVA analysis followed by New-
man–Keuls or Bonferroni multicomparison post hoc tests. The levels of statistical significance
are shown in figure legends. A p-value of 0.05 or less was considered statistical significant. Sta-
tistical analyses were performed using GraphPad Prism 3.03 software (GraphPad, San Diego,
CA).
Results
Body weight and intestinal mucosa integrity
Neurological deficit or sensorimotor dysfunction were not observed in HSV-1 infected mice
throughout the experimental period. No histological anomalies in ileal and colonic mucosa
S. boulardii CNCM I-745 improves HSV-1 induced intestinal dysmotility
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were observed in any of the experimental groups (Fig 2A). Throughout the experiment, body
weight gain and food intake were comparable between HSV-1 injected and control animals,
either receiving S. boulardii CNCM I-745 or not (Fig 2B and 2C).
HSV-1-induced gastrointestinal dysmotility
Ten weeks after IG HSV-1 inoculum, mice experienced a loss in the coordinated motility of
the different intestinal segments compared with non-infected mice (Fig 3). Thus, 10 weeks
post viral inoculum a slower ileal transit (p<0.02 vs control mice) was associated with a
quicker colonic emptying (p<0.05 vs control mice).
Daily supplementation with S. boulardii CNCM I-745 corrected the gastrointestinal dysmo-
tility observed at 10 weeks post viral inoculum (Fig 3). Thus, S. boulardii supplementation nor-
malized the ileal-colonic transit (p<0.02) and corrected the fecal water content and the bead
expulsion time (p<0.05 vs HSV-1 infected mice, Fig 3).
HSV-1-induced neuro-muscular dysfunction
Since a coordinated gastrointestinal motility is largely dependent on the ENS, we assessed ex
vivo the functional integrity of the myenteric plexus measuring the strength of pharmacologi-
cally (carbachol) and electrically induced muscular contractions of ileal segments. The strength
of pharmacologically and electrically induced contractions of ileum segments isolated from
Fig 2. Effect of S. boulardii CNCM I-745 supplementation on mice. Panel A: Representative images of colons
and ileum sections stained with hematoxylin/eosin. Panel B: body weights from 6 weeks after the IG inoculum. Panel
C: daily food intake of mice from week 6 after IG inoculum. n = 8 mice per group. One way ANOVA and Bonferroni
post-hoc test were employed to compare body weight and food intake. F(3,28) = 0.69, p>0.05.
https://doi.org/10.1371/journal.pone.0181863.g002
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HSV-1 infected mice was significantly reduced at week 10 post IG inoculum compared with
controls (p<0.01, Fig 4). S. boulardii CNCM I-745 supplementation abrogated the HSV-1
induced deficit of the ileal neuromuscular unit (p<0.01 vs HSV-1 infected mice, Fig 4).
HSV-1-induced anomalies of the ENS
The network of the ENS is usually mapped by evaluating specific neuronal and glial proteins,
whose distribution and expression are erratic during gut inflammation and dysmotility. Frag-
mentation of intermediate neuronal filaments peripherin and βIII-tubulin, alteration of neuro-
nal nitric oxide synthase (nNOS) levels, and under- or over-expression of the glial marker
S100β are usually associated with intestinal neuropathology and motor dysfunction [9,22].
Fig 3. Effects of S. boulardii CNCM I-745 on gastrointestinal dysmotility induced by HSV-1 infection.
Panel A: Relative distribution of non-absorbable FITC-labelled dextran probe in the intestine (geometric
center, n = 8 per group). ˚ denotes p<0.02 versus control mice; Panel B: Expulsion time (seconds) for a glass
bead inserted into the rectum. * denotes p<0.05 versus control mice; Panel C: Water content of the fecal
pellets expulsed for 1 hour (n = 8 each group). * denotes p<0.05 versus control mice. For all the groups
ANOVA gave an F value which is statistically significant with degrees of freedom.
https://doi.org/10.1371/journal.pone.0181863.g003
Fig 4. Effects of S. boulardii CNCM I-745 on ileal contractility impairment induced by HSV-1. Panel A:
Carbachol-elicited contractions in ileum segments (n = 6–8 per group). Panel B: EFS-elicited contractions in
ileum segments (n = 6−8 per group). One way ANOVA and Newman–Keuls post hoc test were employed to
compare the extension of induced contractions between groups. * denotes p<0.01 versus control mice.
https://doi.org/10.1371/journal.pone.0181863.g004
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To investigate the integrity of enteric nerves, in this study the distribution of peripherin
and βIII-tubulin was evaluated by immunofluorescence staining. Ten weeks after IG adminis-
tration of HSV-1, immunoreactivity of peripherin filaments was significantly reduced in non-
supplemented mice compared with controls (Fig 5A, 5C and 5D). In contrast, the integrity of
βIII-tubulin filaments was preserved even in presence of HSV-1 infection (Fig 5A). S. boulardii
supplementation reduced HSV-1-mediated peripherin damage whereas βIII-tubulin filaments
were unaffected (Fig 5A).
In addition to neuronal damage, IG HSV-1 inoculum induced an activated phenotype in
enteric glial cells. Thus, the number of S100β+ cells in the LMMP of HSV-1 infected mice was
increased compared with controls (p<0.01, Fig 5B). Moreover, S100β protein expression sig-
nificantly augmented in LMMP of HSV-1 infected mice (p<0.05 vs control mice, Fig 5D). S.
boulardii CNCM I-745 supplementation restored the expression of S100β at levels comparable
with those in control mice (Fig 5).
Moreover, HSV-1 infection caused changes in the neurochemical code of LMMP neurons
(Fig 5C and 5D); 10 weeks after HSV-1 exposure substance P (SP) positive nerve fibers were
reduced while nNOS level was higher (p<0.05 vs control mice). S. boulardii CNCM I-745 sup-
plementation moderated the neuroplastic changes in LMMP, preventing variations in expres-
sion and distribution of SP (Fig 5A) and nNOS (p<0.05 vs HSV-1 infected mice, Fig 5C and
5D).
HSV-1-mediated inflammatory changes in the myenteric plexus
To investigate whether the gastrointestinal dysmotility and the neuroplastic changes of the
ENS were associated with an inflammatory process triggered by HSV-1 exposure, we evaluated
the gut level of two relevant pro-inflammatory cytokines (TNF-α and IL-1β) using ELISA. Ten
weeks after IG administration of HSV-1, intestinal levels of both TNF-α and IL-1β increased
in non-supplemented HSV-1 infected mice compared with controls (p<0.05, TNF-α; p<0.02,
IL-1β, Fig 6A and 6B). Indeed, in mice receiving S. boulardii CNCM I-745 supplementation,
the HSV-1-induced surge in inflammatory cytokines was abolished (p<0.05, TNF-α; p = 0.02,
IL-1β, Fig 6A and 6B). HSV-1 infection reduced levels of anti-inflammatory cytokines IL-10
and IL-4 (p<0.05 and p<0.02, respectively, compared with controls; Fig 6C and 6D). S. boular-
dii CNCM I-745 supplementation restored basal IL-4 and IL-10 levels in the gut of HSV-1
infected mice (p<0.05 for IL-10 and p = 0.02 for IL-4, Fig 6C and 6D).
Discussion
By far the most common gastrointestinal motor disorder is IBS, affecting around 11% of the
population globally, and often interfering with normal daily functioning [1,2,3]. Although
three decades of extensive clinical research has attempted to identify a cure for IBS patients the
results are undoubtedly unsatisfactory, mostly because of the complexity of the disease [2].
Moreover, the lack of reliable in vivo animal models mimicking the complexity of IBS symp-
toms has hampered the development of novel therapeutic strategies. [2,4]. In this study, we
took advantage of a novel murine model of intestinal motor disorder, caused by a complex
ENS dysfunction secondary to HSV-1 infection [9], to test the effect of the probiotic yeast S.
boulardii CNCM I-745. We showed that S. boulardii CNCM I-745 supplementation effectively
prevents gastrointestinal dysmotility and mucosal inflammation associated with the persistent
HSV-1 infection of the ENS.
Gut dysmotility, microscopic inflammation, and visceral hypersensitivity are features pres-
ent to varying extents in IBS patients, but are difficult to concurrently reproduce in animal
models [23]. Typically, animal models utilize early-life pathological stressors, i.e., colonic
S. boulardii CNCM I-745 improves HSV-1 induced intestinal dysmotility
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Fig 5. Effects of S. boulardii CNCM I-745 supplementation on HSV-1-induced neuroplasticity in the
enteric nervous system. Panel A: Immunofluorescence analysis for neurofilament peripherin, neurotubules
βIII-tubulin, glial marker S-100β, and neuropeptide substance P (SP). Scale bars 75 μm. Panel B: S100β
positive cells per mm2 were quantified. Panel C: Western blot analysis of peripherin, S-100β, and nNOS in
protein extracts from LMMP. β-actin was used as a loading control. Panel D: Protein amount was quantified
by densitometry analysis. One way ANOVA and Bonferroni post hoc test were employed to compare number
of S100β positive cells in Panel B and amounts of proteins in Panel D. In Panel B, * denotes F(3,28) = 10.88,
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irritation or maternal separation in newborn rats, to mimic at least some of the pathophysio-
logical features of IBS such as the enhanced colonic motor function in response to stress
[24,25]. Although currently there is no clinical evidence of an involvement of neurotropic
viruses in IBS [2], our HSV-1 based model of intestinal dysmotility offers some unique features
relevant to the IBS field, such as the presence of mild intestinal inflammation combined to
structural and functional anomalies of the enteric nerves [9]. Indeed, several studies have dem-
onstrated that IBS patients show a low-grade inflammation throughout the small bowel and
colon therefore affecting nearby enteric nerves through the release of inflammatory mediators,
including interleukins and histamine [7,26,27]. It has also been suggested that enteric nerves
in IBS patients undertake significant phenotypic and molecular neuroplasticity eventually
accounting for symptoms and pathophysiology [28,29]. Indeed, in our model HSV-1 triggered
p< 0.01 compared to control. In Panel D, ANOVA gave an F value which is statistically significant with degrees
of freedom for all the groups; * denotes p< 0.05 compared to control.
https://doi.org/10.1371/journal.pone.0181863.g005
Fig 6. Effects of S. boulardii CNCM I-745 on HSV-1-induced inflammation in the longitudinal muscle
layer with the adherent myenteric plexus (LMMP). TNF-α (Panel A), IL-1β (Panel B), IL-10 (Panel C), and
IL-4 (panel D) quantified by ELISA. Cytokine levels were expressed as pg/mL of tissue lysate. One way
ANOVA and Bonferroni post hoc test were employed to compare the levels of cytokines between groups. In
Panel A, F(3,28) = 37.25, * denotes p<0.05 versus control mice; in Panel B, F(3,28) = 27.18, ˚ denotes
p = 0.02 versus control mice; in Panel C, F(3,28) = 16.73, * denotes p<0.05 versus control mice; in Panel D, F
(3,28) = 28.42, ˚ denotes p = 0.02 versus control mice.
https://doi.org/10.1371/journal.pone.0181863.g006
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significant neuroplastic changes in the ENS (Fig 5) including the fragmentation of intermedi-
ate neuronal filaments markers of intestinal neuropathology associated with gut motor dys-
function [9,22]. Structural and functional alterations in enteric glia cells, such as the increase
in S100β, have been described in animal models of stress-associated gastrointestinal disorders
[30] as well as in IBS patients [31]. These observations suggest an abnormal activation of EGC-
enteric nerve unit contributing to the visceral hypersensitivity in these patients. Moreover,
following HSV-1 IG inoculum we observed an increase in SP positive fibers, as has been re-
ported in colonic mucosa of IBS patients and whose activity correlates with visceral pain
[32,33]. Overall, the changes induced by HSV-1 in the gut mimic most of the anomalies
observed in the ENS of IBS patients, and therefore may represent a dependable animal model
to study novel therapeutic interventions.
Here we reported that administration of S. boulardii CNCM I-745 mitigated the HSV-1
induced alteration of the ENS, restored the gut neuromuscular function (Fig 4), and colonic
stool water resorption (Fig 3). Our data are consistent with available clinical studies reporting
favorable effects of S. boulardii CNCM I-745 supplementation on the gastrointestinal func-
tional anomalies observed in IBS patients [16,34,35,36]. In 2008, Swidsinski et al. also con-
cluded that S. boulardii significantly improved the fecal biostructure and normalized diarrheal
symptoms in patients with chronic idiopathic diarrhea [37]. On the other hand, Bafutto and
colleagues reported that S. boulardii significantly improved GI symptoms in IBS patients and
Abbas and colleagues demonstrated an improvement of quality of live and a significant reduc-
tion in mucosal inflammatory cytokines [34,36]. Interestingly, recent studies reported the
effectiveness of other probiotic yeasts in IBS patients. In a randomized clinical trial on IBS-
diarrhea type, Pineton de Chambrun et al. showed that S. cerevisiae CNCM I-3856 reduced
abdominal pain and discomfort scores. However, this probiotic failed to improve tool fre-
quency and consistency [38].
Probiotic-based treatments are gaining popularity for the treatment of multiple gastrointes-
tinal disorders including IBS [39,40]. A number of hypotheses have been proposed to justify
their use, such as beneficial effects on immune homeostasis of the host intestinal mucosa, pro-
duction of short-chain fatty acids which alter gut motility, and the manipulation of opioid
receptors [41,42,43]. However, the quality of study design, the heterogeneity of treatment pro-
tocols, and variability of treatment (single strains versus mixtures) makes it difficult to demon-
strate the efficacy of probiotic administration in IBS [10,44]. Since studies performed using
intestinal biopsies support the existence of an inflammatory milieu in IBS patients, the effec-
tiveness of specific probiotics may depend on their anti-inflammatory effects [39]. For exam-
ple, Bifidobacterium infantis 35624 demonstrated reproducible anti-inflammatory effects both
in animal models [45] and in vitro and showed efficacy in IBS patients [12,46]. Here we report
that S. boulardii CNCM I-745 administration attenuated HSV-1 induced immune-mediated
inflammatory process and had effects on mucosa and muscular layers of both the small intes-
tine and colon (Figs 3, 4 and 6). Several studies have proven the ability of this yeast to modulate
mucosal inflammation by blunting the activity of nuclear factor κB [47] and mitogen-activated
protein kinases ERK1/2 [48], or by enhancing the expression of peroxisome proliferator-acti-
vated receptor-gamma [49]. In addition, the ability of S. boulardii CNCM I-745 to trap acti-
vated T cells in mesenteric lymph nodes could reduce intestinal inflammation and safeguard
the integrity of the ENS [50]. Indeed, S. boulardii interaction with resident microflora and
intestinal mucosa modulates the intraluminal inflammatory cytokines leading to an improve-
ment in mucosal barrier function or normalization of the activity of the ENS, both accounting
for the amelioration in intestinal motility as it has been suggested for other probiotics [12].
Moreover, S. boulardii treatment significantly decreased blood and tissue levels of proinflam-
matory cytokines and increased anti-inflammatory IL-10 level with a marked improvement in
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the quality of life and bowel-related symptoms [34]. Indeed, this study was designed to investi-
gate the mechanisms of actions of S. boulardii CNCM I-745 in the light of previously described
improvement in quality of life of IBS patients [16,34,51]. Of course, the complexity of IBS etio-
logical factors cannot be reflected in a single animal model. We are aware of the limitations of
our experimental model and further investigations of IBS symptoms treatment by S. boulardii
could take advantage by different in vivo models [52,53].
Overall the results of our study indicate that administration of S. boulardii CNCM I-745
ameliorates gastrointestinal dysmotility that follows HSV-1 IG administration. HSV-1-
induced dysmotility is associated with mild inflammation, thus partially resembling the patho-
physiological picture of IBS patients. Similar to other bacterial probiotics effective on IBS
symptoms, the well-known anti-inflammatory and immuno-modulatory properties of S. bou-
lardii CNCM I-745 [54] appear to be essential for the beneficial effects in our model of gastro-
intestinal dysmotility. In addition, the observations that S. boulardii CNCM I-745 prevents gut
dysbiosis even during antibiotic administration [55,56], might suggest additional mechanisms
of action.
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